Under the terms of the agreement Alnara will obtain exclusive worldwide rights to develop and market liprotamase.
Robert Beall, president and CEO of the Cystic Fibrosis Foundation Therapeutics (CFFT), said: “The Cystic Fibrosis Foundation is excited to enter into a licensing agreement with Alnara for the development of liprotamase, which has the potential to be the first porcine-free pancreatic enzyme therapy for cystic fibrosis patients with pancreatic insufficiency.
“We look forward to working with Alnara to quickly finish the development of liprotamase and bring this promising new treatment option to patients with cystic fibrosis.”